David Martí-Aguado

Dr. David Martí-Aguado

Digestive Disease Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
DMDavid Martí-Aguado
David Martí-Aguado
JCJose Luis Calleja
Jose Luis Calleja
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
JRJuan Carlos Rodríguez-Duque
Juan Carlos Rodríguez-Duque
MAMaría Teresa Arias-Loste
María Teresa Arias-Loste

4 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
DMDavid Martí-Aguado
David Martí-Aguado
ACAna Clemente-Sanchez
Ana Clemente-Sanchez
RBRamon Bataller
Ramon Bataller

1 January 2022 in Radiology
Verified
Journal Article
Closed access
DMDavid Martí-Aguado
David Martí-Aguado
AJAna Jimenez-Pastor
Ana Jimenez-Pastor
ÁAÁngel Alberich-Bayarri
Ángel Alberich-Bayarri
ARALEJANDRO RODRIGUEZ-ORTEGA
ALEJANDRO RODRIGUEZ-ORTEGA
CAClara Alfaro-Cervelló
Clara Alfaro-Cervelló
Luis Martí-BonmatíLuis Martí-Bonmatí
Luis Martí-Bonmatí
For steatosis and iron quantification, automated whole-liver MRI segmentation measurements correlated with histologic data in chronic liver disease and showed similar diagnostic accuracy to manual ... Background Standardized manual region of interest (ROI) sampling strategies for hepatic MRI steatosis and iron quantification are time consuming, with variable results. Purpose To evaluate the perf...

27 September 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
DMDavid Martí-Aguado
David Martí-Aguado
ARALEJANDRO RODRIGUEZ-ORTEGA
ALEJANDRO RODRIGUEZ-ORTEGA
CMClaudia Mestre‐Alagarda
Claudia Mestre‐Alagarda
MBMónica Bauza
Mónica Bauza
EVElena Valero‐Pérez
Elena Valero‐Pérez
Luis Martí-BonmatíLuis Martí-Bonmatí
Luis Martí-Bonmatí
Summary: Background: Histological evaluation of metabolic‐associated fatty liver disease (MAFLD) biopsies is subjective, descriptive and with interobserver variability.Aims: To examine the relationship between different histological features (fibrosis, steatosis, inflammation and iron) measured with automated whole‐slide quantitative digital pathology and corresponding semiquantitative scoring systems, and the distribution of digital pathology measurements across Fatty Liver Inhibition of Progression (FLIP) algorithm and Steatosis, Activity and Fibrosis (SAF) scoring systemMethods: We prospectively included 136 consecutive patients who underwent liver biopsy for MAFLD at three Spanish centres (January 2017‐January 2020). Biopsies were scored by two blinded pathologists according to the Non‐alcoholic Steatohepatitis (NASH) Clinical Research Network system for fibrosis staging, the FLIP/SAF classification for steatosis and inflammation grading and Deugnier score for iron grading. Proportionate areas of collagen, fat, inflammatory cells and iron deposits were measured with computer‐assisted digital image analysis. A test‐retest experiment was performed for precision repeatability evaluation.Results: Digital pathology showed strong correlation with fibrosis (r = 0.79; P < 0.001), steatosis (r = 0.85; P < 0.001) and iron (r = 0.70; P < 0.001). Performance was lower when assessing the degree of inflammation (r = 0.35; P < 0.001). NASH cases had a higher proportion of collagen and fat compared to non‐NASH cases (P < 0.005), whereas inflammation and iron quantification did not show significant differences between categories. Repeatability evaluation showed that all the coefficients of variation were ≤1.1% and all intraclass correlation coefficient values were ≥0.99, except those of collagen.Conclusion: Digital pathology allows an automated, precise, objective and quantitative assessment of MAFLD histological features. Digital analysis measurements show good concordance with pathologists´ scores.

25 March 2021 in European Radiology
Verified
Journal Article
Closed access
PDF file
AJAna Jimenez-Pastor
Ana Jimenez-Pastor
AAAngel Alberich-Bayarri
Angel Alberich-Bayarri
RLRafael Lopez-Gonzalez
Rafael Lopez-Gonzalez
DMDavid Martí-Aguado
David Martí-Aguado
MFManuela França
Manuela França
LMLuis Marti-Bonmati
Luis Marti-Bonmati

Verified
Journal Article
Open access
PDF file
CGCarla Giménez-Garzó
Carla Giménez-Garzó
AFAlessandra Fiorillo
Alessandra Fiorillo
María Pilar BallesterMaría Pilar Ballester
María Pilar Ballester
JRJuan José Gallego Roig
Juan José Gallego Roig
FCFranc Casanova-Ferrer
Franc Casanova-Ferrer
CMCarmina Montoliu
Carmina Montoliu
Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessing different neurological functions: PHES (Psychometric Hepatic Encephalopathy Score) battery, d2, Stroop, Oral SDMT (Symbol Digit Modalities Test), Digit Span, number-letter test, and bimanual and visual-motor coordination tests. NAFLD patients show impairment in attention, mental concentration, psychomotor speed, cognitive flexibility, inhibitory mental control, and working memory. We developed a new, rapid, and sensitive score based on the most affected parameters in NAFLD patients, unveiling that 32% of NAFLD show MCI. Prevalence was similar in NAFL (36%) or NASH (27%) patients, but lower in NAFLD than in cirrhosis (65%). MCI prevalence is significant in NAFLD patients. Psychometric testing is warranted in these patients to unveil MCI and take appropriate measures to reverse and prevent its progression.